Tyra Biosciences doses first patient in Phase 2 study of TYRA-300 for low-grade, intermediate risk NMIBC

Tyra Biosciences, Inc.

SURF302 open-label Phase 2 study of TYRA-300 in FGFR3-altered low-grade IR NMIBC; up to 90 participants at US sites.
Primary endpoint: complete response rate at three months; initial CR data expected first half 2026.
Patients randomized to 50 mg QD or 60 mg QD; additional dosing cohort may be evaluated.
TYRA-300 also being studied in pediatric achondroplasia in BEACH301 Phase 2; first child dosing expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.